Safety, Efficacy, and Biomarker Analysis of a Phase 1 Study of PLK1 Onvansertib + Low-Dose Cytarabine or Decitabine in Relapsed/Refractory AML
By
Yale Cancer Center
FEATURING
Amer Zeidan
By
Yale Cancer Center
FEATURING
Amer Zeidan
Login to view comments.
Click here to Login